Endotoxin-free E. coli biologics expression platform
An engineered E. coli BL21 strain provides a 99% LPS reduction for endotoxin-free biomolecule production. This antibiotic-free, auxotrophic system uses plant phenolics or NSAIDs for growth regulation, optimizing biologics production, including proteins, DNA, and RNA.
Overview
The Endotoxin-Free E. coli Biologics Expression Platform offers a novel approach to biomolecule production using an engineered E. coli BL21 strain with a significant 99% reduction in lipopolysaccharide (LPS) content. This platform is designed to produce proteins, peptides, DNA, RNA, and minicircle DNA without the use of antibiotics, making it safer and more compliant with regulatory standards. The system utilizes an auxotrophic mutant with growth limited to specific nutrient media, regulated by plant-derived phenolics or NSAIDs, ensuring enhanced containment.
Technical specifications
- Engineered Strain: E. coli BL21(DE3) with 99% reduction in LPS, providing an endotoxin-free environment.
- Auxotrophy and Regulation: Mutated essential gene with promoters responsive to plant phenolics or NSAIDs, allowing controlled growth.
- Antibiotic-Free System: Replaces antibiotic markers with essential gene control, using constitutive and inducible promoters.
- ProSiCell Technology: Patent-pending platform for the scalable production of proteins, peptides, DNA, RNA, and minicircle DNA.
- Validation: Plasmid stability and biomolecule expression efficiency evaluated using quantitative PCR, Western blot analysis, and advanced shotgun proteomics.
Technology readiness level
This technology is currently at Technology Readiness Level 3, indicating that it is at the experimental proof-of-concept stage. Ongoing validation includes plasmid stability, expression efficiency, and biological activity assessment of diverse biomolecules, aiming for robust, scalable production suitable for therapeutic and vaccine applications.
About Synbioworks
Biosustain Labs is a biotechnology company focused on the development and production of personalized functional food formulations designed to promote gut health and immunity. Founded in 2020 by researcher Ajay Kalanjana Monnappa, the company utilizes its expertise in microbiology and synthetic biology to create symbiotic formulations, such as its Digest+ product, which combines Bacillus coagulans with pomegranate extract and guar fiber. Its approach centers on applying clinical research to manage or prevent complications related to non-communicable diseases by restoring healthy gut microbiota. The company has gained recognition as a finalist in the PepsiCo Greenhouse Accelerator program for its work in the health and wellness sector. By leveraging evidence-based probiotic and prebiotic innovations, Biosustain Labs aims to provide sustainable, plant-based nutritional solutions that support improved metabolism and digestion across various age groups. Its operations are built upon ten years of research experience, with a focus on delivering holistic health benefits and addressing modern lifestyle-related food habits.
Inquire about this partnering listing
Industry applications
delivered to your inbox.